The Emirates Drug Establishment (EDE) has approved Wegovy (semaglutide), an oral once-daily treatment indicated for long-term weight management in adults living with obesity or overweight associated with weight-related medical conditions.
The Emirates Drug Establishment (EDE) has approved Baxfendy, an innovative medicine containing the active substance baxdrostat, developed by AstraZeneca.
The Emirates Drug Establishment (EDE) has officially granted approval for EURneffy, a novel epinephrine-based treatment available in 1 mg and 2 mg strengths, making the UAE the first country in the region to authorise this innovative therapy.
Emirates Drug Establishment (EDE) has approved Foundayo (orforglipron), an innovative oral treatment for chronic weight management, making the UAE the second country in the world to register the medication, developed by global pharmaceutical company Eli Lilly.
The Emirates Drug Establishment (EDE) has announced the country’s first fully AI-discovered and developed drug candidate by a research team at Insilico Medicine.
The Emirates Drug Establishment (EDE) has set up a task force comprising 16 strategic partners involved in pharmaceutical and logistics supply chains across the UAE, including drug manufacturers, medical warehouses, storage facilities and logistics providers.
